Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Research Foundation Funds 5 COVID-19 Studies for $1.65 Million

  |  Issue: May 2021  |  

Identifying & Meeting the Need

Dr. Knight

Dr. Knight

These five projects and all the other research being done related to COVID-19 and rheumatology will hopefully improve the lives of patients well into the future. This is the vision of the Foundation and why its leadership acted quickly to fund special projects.

To identify these projects, the Foundation issued a Notice of Special Interest and evaluated projects as part of its regular grants cycle, which simplified and expedited the review process. A total of 24 applications were received in response to the special notice. Like the application and review process, the funding process was also accelerated—normally, it takes about a year for grant monies to be issued, but for the five COVID-19 projects, funds were distributed less than six months after the grant applications were submitted for review. Project reports are expected by the end of 2021, and formal publications are expected in mid- to late-2022.

ADVERTISEMENT
SCROLL TO CONTINUE

“The Foundation is very proud to be the leading private funder of rheumatology research and training in the United States,” Dr. Bridges says. “By responding quickly to the COVID-19 pandemic, we hope the research we fund will have a lasting positive impact on the quality of life and outcomes of the patients we care for.”

Kimberly Retzlaff is a freelance medical journalist based in Denver.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020 Apr;5(11):e138999.
  2. Landhuis E. ‘Spider-Man’ immune response may promote severe COVID-19. Scientific American. 2020 Apr 28.
  3. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020 Apr 23;382:e38.
  4. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020 Nov 18; 12(570):eabd3876.
  5. Shi H, Zuo Y, Gandhi AA. Endothelial cell-activating antibodies in COVID-19. MedrXiv. Jan. 20, 2021.

Related Articles

    Telehealth Brings Opportunities to Enhance Patient Care

    During an ACR webinar in August, presenters discussed multiple aspects of telehealth in rheumatology, especially related to rheumatology fellowship training. They agreed that although telehealth represents one potential avenue to improve patient access to treatment for rheumatic disease, we must keep identifying the best ways to employ telehealth to enhance care. Impact of Pandemic Telemedicine…

    Telerheumatology: What’s Next?

    In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.

    What’s Next for Telehealth after the COVID-19 Public Health Emergency?

    Do you remember where you were when the COVID-19 Public Health Emergency (PHE) was declared on Jan. 31, 2020? While it may seem like yesterday, you would be forgiven for not recalling your exact location over three years ago during what felt like an incredible whirlwind for the healthcare industry. One possible location you may…

    Rheumatology in a COVID & Post-COVID World

    Jane’s* hands and wrists had been swollen and painful for about eight weeks. Lab findings in the ambulatory consult that came to our office revealed a cyclic citrullinated peptide antibody count >250 u/mL. We all know where this story goes, including how important the early treatment window is. Our clinic reviews all consults and tries…